Loading quotes...

Forecast

The analysts' average price target is €12.00 (+48.15%). The median is €13.40 (+65.43%).

Buy	15
Hold	6
Sell	0

News Go to news feed

Iovance Biotherapeutics raises annual guidance after strong demand for Amtagvi and Proleukin

Strong market demand for the cancer therapies Amtagvi (Lifileucel) and Proleukin has led Iovance Biotherapeutics to significantly raise its annual forecast. The company is expanding its TIL therapy platform and broadening the clinical pipeline for additional solid tumors. Despite a weak overall market, investors are drawing the stock higher, signaling company-specific momentum. » More on finanzen.net
Iovance raises 2026 revenue forecast after strong demand for Amtagvi

Iovance raised its 2026 revenue forecast to $410–420 million, supported by rising U.S. demand for Amtagvi and Proleukin. Shorter production times and more than 110 treatment centers are driving growth and pushed the stock up about 10% to a 52-week high. The business remains based on tumor-infiltrating lymphocytes (TIL), which are increasingly entering clinical practice for solid tumors. » More on finanzen.net
Iovance Biotherapeutics accelerates revenue growth after successful launch of Amtagvi

Iovance Biotherapeutics is commercializing Amtagvi, the world’s first approved personalized TIL cell therapy for advanced melanoma. Rapid onboarding of specialized treatment centers and rising patient demand are driving dynamic revenue acceleration in the current fiscal year. Analysts view the first-mover advantage and the successful market entry as drivers for further operational growth. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Iovance Biotherapeutics has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Iovance Biotherapeutics had revenue of €87.02M and net profit of -€41.46M

(EUR)	June 2026	YoY
Revenue	87.02M	71.08%
Gross profit	48.82M	419.76%
Net profit	-41.46M	56.24%
EBITDA	-36.37M	57.79%

Fundamentals

Metric	Value
Market capitalization	€5.9B
Number of shares	452.97M
52-week high/low	€13.73 - €1.57
Dividends	No
Beta	0.76
P/E ratio	-19.97
PEG ratio	-0.36
P/B ratio	8.91
P/S ratio	20.32

Company profile

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Name	Iovance Biotherapeutics
CEO	Frederick G. Vogt
Headquarters	San Carlos, ca USA
Website	iovance.com
Sector	Health Care
Industry	Biotechnology
IPO	10/15/2010
Employees	975